The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The potential use of proteomics for predicting relapse in patients with MDS undergoing alloSCT
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the potential use of proteomics to predict relapse in patients with myelodysplastic syndromes (MDS) undergoing allogeneic stem cell transplantation (alloSCT). The study identified two proteomic signatures, the hallmark complement pathway and the hallmark allograft rejection pathway, that were overexpressed in patients who relapsed, highlighting the potential of proteomics to provide insights into disease biology beyond genomic alterations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
